USF Research News

USF faculty and TransGenex co-founder receives Global Corporate Award in Nanotechnology

April 26, 2014
The Global Corporate Alliance honors Shyam Mohapatra with a global corporate award in nanotechnology.

- Dr. Shyam S. Mohapatra, a faculty and an Associate Dean at the USF and the co-founder of TransGenex Nanobiotech, Inc. (TGN), Tampa, was honored for his contributions to nanotechnology, on April 26 at the Second Annual Global Corporate Awards Celebration, held at the University Club, One Tampa City Center, Tampa, Florida.

Global Corporate Awards (GCA), an alliance of Asian Indian Chamber of Commerce, USA; Sino European Commercial Center, India Business Group and Indo-American Society and Maharastra Chamber of Commerce, industry and Agriculture) was established in 2013 to honor innovators and entrepreneurs, out-of-box thinkers and brave trail blazers. Describing the mission of the GCA Mr. H.E. Abdulkalam Abdul Momen, who is currently the Vice President of the UNICEF Exec Board and serves as the chairman of the Board of GCA Advisors, said “ GCA is an unique initiative to recognize, applaud and salute those achievers and leaders who have made their mark and do it again and again everyday”.

Dr. Shyam Mohapatra is a Distinguished Health Professor at the University of South Florida (USF) College of Medicine and directs the USF Nanomedicine Research Center. He also serves as the Associate Dean of Graduate Programs at the College of Pharmacy and is involved in creating on-line programs in nanotechnology. Dr. Mohapatra is also co-founder of a nanobiotech company, TransGenex Nnaobiotech Inc (TGN), that is engaged in commercializing nano-scale biomedical technologies. To its existing platforms, such as ULTraPID™ for diagnosis and TARGETTM for nanopharmaceutics, this year TGN has added a three-dimensional multi-cell tumor (“Tumor- on- a-dish”) platform, which aims to facilitate cancer drug discovery, drug development and personalized cancer treatment.

TGN is collaborating with USF on this latter platform and has recently obtained a federal (National Cancer Institute) SBIR Phase I contract to further develop this project. This is the 7th federal contract that TGN has been able to procure. The company is exploring opportunities in US, India, Latin America and China and aims to commercialize products from this and the other platforms within the next 2-3 years.

In commenting on the award, Dr. Shyam Mohapatra said, “we and the world is still learning to harness this emerging nanotechnologies for exciting and powerful biomedical applications globally, and I am honored to be given this award in this area, but be recognized on a platform where Dr. Kiran Patel, the well known business tycoon and philanthropist in Tampabay area was recognized for his trail-blazing innovations and entrepreneurship in health care business”.